Cytokinetics, Incorporated (CYTK) Rises: Stock Jumps 12.6% – Tale of the Tape

December 24, 2014 Technicals 0

Zacks

Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise more than 12% on the day. The rise came as the company announced the expansion of its existing collaboration with Astellas Pharma Inc. to facilitate the development of CK-2127107, a fast skeletal troponin activator, in Spinal Muscular Atrophy (SMA), which led to more shares changing hands than in a normal session. This reverses the recent trend of the company, as the stock is now trading above the volatile price range of $4.40 to $4.88 over the past one-month time frame.

None of the estimates for this stock were revised in the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cytokinetics sports a Zacks Rank #1 (Strong Buy), while its Earnings ESP is 0.00%.

Investors interested in the med-biomed/gene industry may also consider Affymetrix Inc. (AFFX), carrying the same rank as Cytokinetics.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply